Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

KATERZIA 1 MG/ML SUSPENSION

Amlodipine
$4.1914per ML

Strength

1 mg/mL

Manufacturer

Azurity Pharmaceuticals Inc.

NDC

52652500101

Classification

Brand

Dosage Form

SUSPENSION

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

AMLODIPINE BENZOATE

Approval Type

New Drug (NDA)

FDA Application

NDA211340

On Market Since

8/15/2019

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Dihydropyridine Calcium Channel Blocker
Dihydropyridines

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+3.0%

1Y

+2.6%

3Y

+18.7%

5Y

+28.3%

All

+32.8%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

TIAZAC ER 180 MG CAPSULE
Brand
00187261330•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 180 MG CAPSULE
Brand
00187261390•Bausch Health US LLC
$1.5060
per EA
MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2097
per ML
TIAZAC ER 360 MG CAPSULE
Brand
00187261630•Bausch Health US LLC
$2.7628
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261690•Bausch Health US LLC
$2.7628
per EA
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
NORLIQVA 1 MG/ML SOLUTION
Brand
46287003515•CMP Pharma, Inc.
$3.2067
per ML
CARDIZEM LA 120 MG TABLET
Brand
00187204530•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 120 MG TABLET
Brand
00187204590•Bausch Health US LLC
$3.6467
per EA
CARDIZEM LA 180 MG TABLET
Brand
00187204630•Bausch Health US LLC
$3.8314
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy